Since inhibition of β2-M results in iron overload, increase in reactive oxygen species and decreases in stress response proteins in vitro, we tested if treatment with anti-β2-M Ab could sensitize prostate cancer cells to clinically used chemotherapeutic agents. Here, B2M is linked to prostate cancer.